908 Devices (MASS)

• Market cap: $71.7M
• 1 day: 6.19%
• 5 days: -0.96%
• 1 month: -19.53%
• 3 months: -44.02%
• 6 months: -61.06%
• Year to date: -79.23%
• 1 year: -76.29%
• 5 years: -95.80%
• 10 years: -95.80%
• Sector: Industrials
• Industry: Measuring & Controlling Devices

About: 908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.

Employees: 230

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

2.94% less ownership

Funds ownership: 56.66% [Q2] → 53.73% (-2.94%) [Q3]

4% less funds holding

Funds holding: 90 [Q2] → 86 (-4) [Q3]

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

35% less call options, than puts

Call options by funds: $54K | Put options by funds: $83K

36% less capital invested

Capital invested by funds: $101M [Q2] → $64.8M (-$35.8M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 94% upside
• Avg. target: $7.33 256% upside
• High target: $12 483% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Stifel Daniel Arias 22% 1-year accuracy 4 / 18 met price target	191% upside $6	Buy Maintained	13 Nov 2024
Leerink Partners Puneet Souda 60% 1-year accuracy 3 / 5 met price target	94% upside $4	Market Perform Downgraded	13 Nov 2024
Leerink Partners	483% upside $12	Outperform Maintained	17 Oct 2024